Germline BRCA1 and BRCA2 pathogenic variant carriers are recognized to be at increased risk for multiple cancers including breast, ovarian, pancreatic, and prostate cancer, with risk management recommendations for these cancers included in BRCA1/2 guidelines. This evidence concerns the gene BRCA2 and prostate carcinoma.